News

InhibOx Closes Successful Funding Round to Fund New Premises and International Growth

Submitted by InhibOx on June 17, 2011 - 17:25

InhibOx builds momentum on the back of recent successes

Oxford, UK, June 17th 2011. InhibOx Ltd, the specialist in novel and effective computational methods for drug discovery, today announces the successful completion of its latest funding round. The company was supported by its existing shareholders, including IP Group plc, the University of Oxford, Angel investors and the management team. The investment round was fully subscribed.

InhibOx Shortlisted for Prestigious Red Herring 100 Award

Submitted by InhibOx on May 19, 2011 - 23:51

Oxford, 19 May 2011 – InhibOx announced today it has been selected as a Finalist for Red Herring's Top 100 Europe award, a prestigious list honouring the year’s most promising private technology ventures from the European business region.

InhibOx and COSMIC Discoveries Align to Deliver  Full Service Drug Discovery Offering

Submitted by InhibOx on March 15, 2011 - 11:11

New service supports big pharma’s drive to outsourcing by offering highly sophisticated technologies for drug discovery chemistry with leading computer-aided drug design services

InhibOx

InhibOx Announces Scopius-5 – The First 100 Million+ Compound 3D Drug Candidate Design Database

Submitted by InhibOx on December 17, 2010 - 15:33

Scopius is the largest available curated 3D compound and fragment database

Oxford, UK, December 17, 2010 - InhibOx Ltd, the specialist in novel and effective computational methods for drug discovery, today announces the launch of Scopius-5 – the world’s largest currently available drug discovery screening database and the first system to pass 100 million compounds. Scopius-5 is a unique and powerful resource that will enable new levels of innovation and rigor to screening processes in drug discovery.

InhibOx announces LOx - a new system for versatile fragment-based design

Submitted by InhibOx on October 28, 2010 - 09:30

LOx offers a new pharmacophoric linking approach, integrated with Scopius, the largest available curated 3D compound and fragment database

Oxford, UK, October 28th, 2010. InhibOx Ltd today announces LOx 2.0 - a flexible new system to identify and optimize drug lead candidates through preserving and linking critical features with new scaffolds. Lox 2.0 carries fragment-linking tools a stage further and delivers a powerful approach for drug discovery scientists seeking to alter the core scaffold of a lead series to maximize activity, optimize physical properties and to create novel intellectual property.

InhibOx Chairman Prof. Graham Richards CBE in List of UK’s Top 100 Scientists

Submitted by InhibOx on October 7, 2010 - 15:31

Professor Richards recognized for significant contributions to science and business

Oxford, UK, 7th October 2010. InhibOx Ltd (Oxford, UK)

InhibOx, the Oxford-based computational drug discovery specialist, is proud to announce that its Founder & Chairman, Professor W. Graham Richards, CBE, appeared in today’s publication in The Times of “Eureka 100: The 100 Most Important People in British Science”.

Cambridge Crystallographic Data Centre and InhibOx Create New Powerhouse in Drug Discovery and Development Services

Submitted by InhibOx on July 7, 2010 - 09:00

New service supports big pharma’s drive to outsourcing by offering highly sophisticated technologies for drug discovery with cloud computing and software-as-a-service facilities

Oxford and Cambridge, UK, July 7, 2010. InhibOx Ltd (Oxford, UK) and the Cambridge Crystallographic Data Centre (Cambridge, UK) announce they that have joined forces to create a uniquely powerful drug discovery service offering. Users of the new service will benefit from the shared depth of expertise that includes extensive commercial drug discovery experience and from the leading proprietary technologies developed by the Oxford and Cambridge bodies.